Please try another search
For the fiscal year ended 31 March 2022, Stella Pharma Corp revenues decreased 51% to Y100.1M. Net loss applicable to common stockholders increased 16% to Y767.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Contract research income decrease of 45% to Y17.8M (income), Other Non-Operating Income decrease of 99% to Y23K (income).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 47 | 92 | 61 | 54 |
Gross Profit | 40 | 68 | 54 | 48 |
Operating Income | -165 | -139 | -163 | -303 |
Net Income | -164 | -140 | -165 | -295 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 3926 | 4141 | 4196 | 4329 |
Total Liabilities | 1256 | 1308 | 1350 | 1577 |
Total Equity | 2670 | 2833 | 2846 | 2752 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review